Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Enterprise Value (2022 - 2026)

Zentalis Pharmaceuticals has reported Enterprise Value over the past 6 years, most recently at -$211.8 million for Q1 2026.

  • For Q1 2026, Enterprise Value rose 33.89% year-over-year to -$211.8 million; the TTM value through Mar 2026 reached -$211.8 million, up 33.89%, while the annual FY2025 figure was -$245.9 million, 30.13% up from the prior year.
  • Enterprise Value for Q1 2026 was -$211.8 million at Zentalis Pharmaceuticals, up from -$245.9 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$30.4 million in Q1 2022 and troughed at -$482.8 million in Q4 2023.
  • A 5-year average of -$155.3 million and a median of -$54.8 million in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: crashed 1026.8% in 2023 and later soared 86.12% in 2024.
  • Year by year, Enterprise Value stood at -$42.8 million in 2022, then crashed by 1026.8% to -$482.8 million in 2023, then grew by 27.11% to -$351.9 million in 2024, then surged by 30.13% to -$245.9 million in 2025, then rose by 13.88% to -$211.8 million in 2026.
  • Business Quant data shows Enterprise Value for ZNTL at -$211.8 million in Q1 2026, -$245.9 million in Q4 2025, and -$41.5 million in Q3 2025.